● Single award · contract
COVID-19 Oral Antiviral MK-4482 (Molnupiravir)
A single federal award, with both ends of the trail linked.
$2.2B
total award value
2021
action date
25 mo
period
W911QY21C0031
PIID
Awarding agencyDepartment of Defense →
RecipientMerck Sharp & Dohme LLC →
Place of performanceNew Jersey →
CategoryNAICS 325412PSC 6505
Competed?Not recorded✓ from source
Total (exact)$2,205,000,834
More awards to Merck Sharp & Dohme LLC
awarded 2017$1.5B
awarded 2017$236.3M
awarded 2024$155.8M
awarded 2021$102.3M
awarded 2014$77.9M
More from Department of Defense
awarded 2016$51.3B
awarded 2017$35.1B
awarded 2017$34.9B
awarded 2001$34.2B
awarded 2011$32B
🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; anything we compute or infer (corporate parents, districts, competitors) is ≈ inferred and worded carefully, never asserted as fact.